Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.40 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.40 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1121004 | 0.83 | L3MBTL1 (0.50) | MEN1KMT2AAPAF1L3MBTL1SCN9A | |
| SCHEMBL30411682 | 0.83 | L3MBTL1 (0.49) | MEN1KMT2AL3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL10681003 | 0.76 | MEN1 (0.61) | MEN1KMT2AAPAF1L3MBTL1SCN9A | |
| SCHEMBL12015 | 0.76 | CCR1 (0.41) | L3MBTL1TDP1RAB9ANOS3NOS1 | |
| SCHEMBL29520064 | 0.76 | CCR1 (0.41) | L3MBTL1TDP1RAB9ANOS3NOS1 | |
| SCHEMBL4375485 | 0.75 | NOS3 (0.55) | MEN1KMT2AAPAF1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3177144 | 0.75 | SMN1; SMN2 (0.54) | MEN1KMT2AAPAF1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4234646 | 0.74 | ALDH1A1 (0.65) | MEN1KMT2AAPAF1L3MBTL1ALDH1A1 | |
| Sulfanilamide SCHEMBL28100665 | 0.74 | LMNA (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL2345370 | 0.74 | MEN1 (1.00) | MEN1KMT2AAPAF1SCN9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8957087-B2 | Heterocyclic substituted acardite derivate and application thereof | Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) | 2015-02-17 | — | — | US | disclosed |
| EP-2428506-B1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) | 2014-03-05 | — | — | EP | disclosed |
| EP-2428506-A1 | HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF | Jiangsu Provincial Institute Of Materia Medica Co. (CN) | 2012-03-14 | — | — | EP | disclosed |
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053192-A1 | Heterocyclic Substituted Acardite Derivate and Application Thereof | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 | MEN1 2063/4885KMT2A 1811/4885APAF1 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.